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Abstract
BACKGROUND: The initial draining lymph node for a primary
tumor is referred to as the “sentinel” node. Firstly adopted in
the management of patients with cutaneous melanoma and
breast cancer, it is now widely tested in cervical cancer. In pa-
tients with cervical cancer, lymph node status is the most im-
portant prognostic factor for survival. In patients with cervical
cancer FIGO stage I and II pelvic lymph node metastases are
expected in 0–16 and 24.5–31% and para-aortic lymph node
metastases are expected in 0–22 and 11–19% of patients.
The removal of pelvic and para-aortic lymph nodes is essential
for assessing the biology of the disease. Lymphoscintigraphy
enables the visualisation of lymphatic drainage patterns from
a great variety of tumour sites prior to surgery. Therefore, the
current procedure is to perform the pre-operative mapping
of sentinel nodes by static and/or dynamic lymphoscintigraphy,
followed by in vivo identification using a gamma detection probe
and selective surgical resection.
MATERIAL AND METHODS: Between 2001–2003, 37 patients
with cervical cancer FIGO stage I-IIa were deemed to be quali-
fied to undergo lymphoscintigraphy. The day before surgery
99m Tc-nanocolloid (100 MBq; 0.5–1.0 ml in volume) was ap-
plied in each quadrant of the cervix or around the tumor.
The static scintigraphic scans were performed after 2 hours p.i.
using a dual-head large-field-of-view Siemens gamma-camera
equipped with high resolution collimators. SNs were identified
intra-operatively using a handheld gamma detection probe
(Navigator GPS-Tyco) and intra-operative lymphatic mapping
with blue dye. After a resection of the SNs, a standard radical
hysterectomy with pelvic and low para-aortic lymph node dis-
section was performed. Tumor characteristics were compared
with sentinel node detection and with the histopathological and
immunohistochemical results.
RESULTS: The scintigraphy showed a focal uptake in 35 of the 37
patients. In all women one or more sentinel lymph nodes were
identified intra-operatively. Of them, 24 patients had those lo-
cated  bilaterally. Histologically positive SNs were found in
5 women (13.5%).
CONCLUSIONS: A combination pre-operatively administered
radioactively labelled albumin with blue dye allows the success-
ful detection of SN in patient with cervical cancer. This tech-
nique will result in a real advance in the less aggressive mana-
gement of patients with early stage cervical cancer. Sentinel
lymph node status may be representative of the pelvic lymph
nodes status in cervical cancer and thus could provide impor-
tant information for further treatment.
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Introduction
Sentinel nodes (SNs) are defined as the first draining lymph
nodes from a tumour when lymphatic metastases occur [1].
In 1977 Cabanas was the first to define the term “sentinel lymph
node” and to test the concept in penile cancer [2]. He injected
radiographic contrast media into the dorsal lymphatics of the pe-
nis in patients in penile carcinoma, followed by radiographic im-
aging of the penis. The first visualised inquinal lymph node was
called the sentinel lymph node (SLN). This concept was then adop-
ted in patients with melanoma [3–7], breast cancer [8–11] and
more recently in surgery for colorectal [12] and gastric cancer
[13] and in ginecology, by Lavenback and Burke for vulvar cancer
[14], by Dargent et al. for cancer of the cervix.
Lymph node metastasis is one of the most important prog-
nostic factors in patients with cervical carcinoma. Dissection
of the regional pelvic lymph nodes is incorporated into the proce-
dures for radical hysterectomy but is accompanied by significant
morbidity. Lymphadenectomy increases the duration of the pro-
cedure, the amount of blood loss from vessels during surgery,
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the incidence of post-operative ileus, and the risk of infection.
In addition, up to 5% of patients complain of lymphedema of the
thighs or legs. Pre-operative diagnosis of lymph node involvement
would prevent unnecessary surgery. When the results of diagnos-
tic procedure including lymphoscintigraphy are positive,  patients
could be treated with combined chemo- and radiotherapy instead
of undergoing a radical hysterectomy [15].
The aim of this study was to perform pre-operative lymphatic
mapping in patients with cervical cancer and then confirm the pre-
sence of sentinel nodes using a gamma detection probe and blue
dye for assessing the clinical usefulness of this method and the po-
ssibility of avoiding radical hysterectomy and lymph node dissection.
Material and methods
Between years 2001–2003 lymphatic mapping and sentinel
node detection were performed in 37 patients with cervical can-
cer FIGO stage I–IIa. 36 patients had squamous cell carcinoma
and 1 patient had adenocarcinoma of the cervix. The informed
consent of the patients was obtained.
 The day before surgery 99m Tc-nanocolloid (100 MBq, 0.5–1 ml
in volume) was applied in each quadrant of the cervix or around
the tumor (about 5–10 mm deep into the cervix). In all patients
about 2 hours p.i. of the tracer the static scintigraphic scans were
performed. This scintigraphy was detected using a dual-head
large-field-of-view Siemens gamma-camera equipped with high
resolution collimators. The first persistent focal accumulation which
appeared was considered to be a sentinel node.
On the day of surgery, after the induction of general anesthe-
sia, 4 ml of Patent Blue was injected into the cervix at the same
location and depth as the radioisotope. The abdomen was opened
by means of a midline incision, the peritoneal cavity was inspec-
ted and an incision was made in the pelvic peritoneum to expose
the retroperitoneum. The retroperitonem was then visually inspec-
ted and scanned with a hand-held gamma counter (Navigator GPS)
to locate the sentinel node. The pelvic and para-aortic regions
were surveyed. Lymph nodes that appeared darker then other
nodes or had a blue color were considered to be sentinel nodes.
The radioactive lymph nodes identified with the gamma probe were
removed and the radioactivity was measured ex vivo. If the counts
were at least 10-fold above the background radiation levels the
node was considered to be a sentinel node. All hot and/or blue
nodes were dissected, sampled, and numbered for separate patho-
logic examinations. The operating surgeons did not attempt to dis-
sect sentinel nodes from the surrounding fat pat. The final number
of sentinel nodes was counted by a pathologist. Subsequently,
a complete pelvic and, in some cases, para-aortic lymphadenecto-
my was performed. Sentinel nodes were submitted for hematoxylin
and eosin staining and, if negative, unstained slides were prepared
for cytokeratin immunohistochemical analysis (cytokeratin 19).
Results
The intra-operative detection of sentinel nodes was success-
ful in 36 cases (97.30%). Only in one patient was the sentinel node
not found. In this case, the lymph nodes exposed during surgery
were enlarged, hard and creating conglomerations along external
hip vessels. This patient, just like our other patients, had not
undergone radiotherapy treatment. Moreover, she had no history
of inflammation in the pelvic minor area/region. The mean num-
ber of sentinel nodes detected was 3.43 (range 0–7). The total
number of sentinel nodes found was 119.
In 28 patients (75.68%) the sentinel nodes were blue and ra-
dioactive, in 2 cases (5.41%) only blue and in 6 cases (16.22) only
radioactive. Out of 119 sentinel nodes detected, 92 (in 77.31%)
were found in the region of hypogastric artery division.
The scintigraphy showed a focal uptake in 35 of the 37
patients. At least one sentinel node (hot spot) was detected in
these patients. In 13 cases they were localized next to the cervix
(in 6 patients unilaterally and in 7 cases bilaterally). The other
cases had hot spots placed above and laterally to the cervix on
the pelvic walls. Of them, in 17 cases, there were bilateral hot
spots. Histologically positive SLNs were found in 5 women. One
patient with metastases in the lymph nodes had a false negative
sentinel node.
Four examples of sentinel nodes are presented on the Figure 1:
Sentinel nodes: a) bilateral on the pelvic walls, b) bilateral next to
the cervix., the Figure 2: Sentinel nodes: a) unilateral on the pelvic
walls,  b) unilateral next to the cervix.
Discussion
Lymphatic mapping is a promising strategy to confirm nodal sta-
tus and minimize post-operative morbidity in patients with early cer-
vical cancer. Previous investigators have described the concept dur-
ing laparotomy, with blue dye during laparoscopy, or with external
gamma probes after the laparoscopic removal of nodes [16–19].
Dargent et al. were able to find a blue-dyed lymph node (they
injected Patent Blue Violet intracervically) after the systematic lapa-
roscopic dissection of the pelvic sidewall in 25 of 35 patients with
Figure 1. Sentinel nodes. A. Bilateral on the pelvic walls; B. Bilateral next
to the cervix.
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early cervical cancer [15, 20]. Failure to identify the sentinel lymph
node was related to the quantity of injected blue dye, but not to
tumor stage, prior conization or tumor  volume. They found a 100%
sensitivity using only blue dye injection, but the problem was the
rate of false negatives [19, 20].
O’Boyle et al. identified a total of 23 SLN in 12 of 20 patients
(60%) using only a patent blue dye injection. In 4 patients with meta-
static nodal disease, three had tumors involving a sentinel node
and the fourth had no identifiable blue-dyed node [19, 21]. The
visual detection of dye uptake in lymph nodes is sometimes diffi-
cult [22]. Failure to identify SLN may be due to an insufficient quan-
tity of injected patent blue dye [20], the disruption of lymphatic chan-
nels during dissection, or  the poor operative exposure of lympha-
tic tissues [19, 21]. A detection rate of sentinel nodes of 78% was
obtained by Malur et al. by a pre-operative injection of Albu-Res
labeled with the radioactive isotope 99m Tc and/or an intra-operative
injection of Patent Blue Dye in a series of 50 patients with cervical
cancer [15, 23]. After a combined injection of radioactivity labelled
albumin and blue dye, the detection rate, sensitivity, and negative
predictive values were 100% in this study. Verheyen et al. [15, 18]
using a similar technique in patients with stage I B and II A cervical
carcinoma in with laparoscopic lymph node dissection was followed
by laparotomy and radical histerectomy and pelvic lymph node dis-
section. In seven out of 10 patients a sentinel node could be iden-
tified. Lavenback et al. studied 39 patients by combining a pre-
-operative lymphoscintigraphy with 99m Tc-nanocolloid with intra-ope-
rative lymphatic mapping with isosulfan blue and a handheld gam-
ma probe. The sensitivity of sentinel node biopsy was 87.5% while
the negative predictive value was 97% [24].
 Isosufan blue dye is used for dye-guided sentinel lymph node
biopsy for visual detection. According to the initial experience
of using only dye-guided sentinel node biopsy, the identification
rates of sentinel lymph nodes ranged between 66–82% [25]. Ra-
dionuclides for lymphatic mapping should be a few hundred na-
nometers in size to permeate the lymphatic vessels and remain in
the sentinel lymph nodes. However, technetium-99m HAS is too
small ( < 5 nm) to be retained in the sentinel lymph nodes and
technetium-99m TC is too big ( > 500 nm) to migrate through
the lymphatic vessels compared with technetium-99m colloid al-
bumin [26, 27]. These factors contributed to low success rate
of sentinel node biopsy with the hand held gamma probe detec-
tor. Combining isosulfan blue dye with 99mTc colloid albumin should
be used for the lymphatic mapping as this combination can im-
prove the rate identification of SNs up to 100%, and seems to be
the best way to accurately detect sentinel lymph nodes [27].
If sentinel lymph nodes are histologically negative by immediate
frozen section examination, extensive pelvic lymph node dissec-
tion can be omitted. However, it may be difficult to detect the mi-
crometastasis of cancer cells by the frozen section of SNs. To com-
pensate for these false negatives, it would be helpful to examine
multiple sections of sentinel lymph nodes especially with immu-
nohistochemical staining [27].
In this paper, we describe a complete laparoscopic approach
of SNs detection using a combination of blue dye, a hand held
gamma probe and isotopic detection in patients with early stage
cervical cancer. Our study shows that after an intra-cervical injec-
tion of 99mTc-nanocolloid, sentinel nodes can be detected intra-ope-
ratively in 97.3% of patients by using an endoscopic gamma probe.
A combination of these techniques increases the detection rate.
On the basis of the results obtained, the concept of sentinel
node seems to be true in cervical cancer. The combination
of radioisotope and dye technique allowed the detection of sentinel
nodes in almost all cases of cervical cancer. Pre-operative lym-
phoscyntigraphy enables the surgeon to ascertain the presence
of sentinel nodes and their rough localization.
Sentinel node mapping (combined use of a radioisotope and
blue dye injection) is a promising technique for use in patients with
early stage cervical cancer, it could be considered as the final diag-
nostic step before applying a therapeutic plan. Sentinel lymph node
biopsy is less invasive than complete pelvic lymph nodes dissec-
tion and lowers both post-operative morbidity and costs.
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